Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 4
1(20.0%)
Phase 1
1(20.0%)
5Total
N/A(3)
Phase 4(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02871180Not ApplicableCompleted

Late Night Snack and Insulin Glargine

Role: lead

NCT02667769Not ApplicableUnknown

Comparison of Two Protocols on the Implementation of a Fasting Day in Type 1 Diabetes

Role: lead

NCT02639130Phase 4Completed

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

Role: lead

NCT02673554Phase 1Completed

The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP

Role: lead

NCT00740012Not ApplicableCompleted

Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®)

Role: lead

All 5 trials loaded